Novel SRRM2-Targeted CAR-T cells in a Relapsed and Refractory Multiple Myeloma Patient with Extramedullary Diseases: a case report

Multiple myeloma is a cancer of the plasma cells, the white blood cells responsible for producing antibodies to fight infection. In this disease, these cells grow out of control, crowding out healthy blood cells and damaging bones. For many patients, the disease eventually returns after initial treatments, becoming resistant to standard drugs. When it spreads beyond the bone marrow into soft tissues, a condition known as extramedullary disease, the outlook becomes even more difficult. In recent years, a type of immunotherapy called CAR-T cell therapy has offered new hope. This approach involves taking a patient's own immune cells, engineering them in a lab to recognize a specific marker on the cancer cells, and then infusing them back into the body to hunt down the tumor. While therapies targeting a marker called BCMA have shown promise, they can cause severe side effects and the cancer sometimes returns. Scientists are now searching for new targets on cancer cells that might offer a safer and more effective way to treat these stubborn cases.

In a recent case report, researchers describe the experience of a sixty-year-old man with relapsed and refractory multiple myeloma who had developed tumors outside his bone marrow. After failing numerous standard treatments, including drugs that block protein production and antibodies that target cell surface markers, the patient was enrolled in a clinical trial for a novel therapy. Instead of targeting the usual markers, this treatment focused on a protein called SRRM2. While this protein is normally found inside the nucleus of healthy cells, the researchers found that in this patient's cancer cells, it had moved to the surface, making it a visible target for the immune system. The team engineered the patient's T cells to recognize and attack this specific protein, creating a custom-made army designed to seek out the cancer.

The treatment began with a short course of chemotherapy to clear space in the body for the new cells. On the day of the infusion, the patient received a dose of the engineered SRRM2-targeted CAR-T cells. Within weeks, the therapy worked quickly. By the twenty-first day, the engineered cells had multiplied significantly in the patient's bloodstream. Imaging scans showed that a large tumor mass near the spine and lungs had completely disappeared. A bone marrow examination revealed that the abnormal cancer cells had largely vanished, and the patient's severe bone pain had subsided. By the twenty-eighth day, the patient had achieved a very good partial response, a significant improvement where the disease is greatly reduced but not entirely gone. Throughout this process, the treatment remained remarkably gentle. The patient experienced only a mild fever and a slight rise in certain immune signals, a condition known as cytokine release syndrome, which is a common reaction to such therapies. Unlike other similar treatments that often cause severe inflammation or nerve damage, this approach did not produce those dangerous side effects.

However, the story also highlights a major challenge in this field. While the initial results were impressive, the engineered cells did not stay in the body for long. By the sixtieth day, the number of active cancer-fighting cells had dropped significantly. Ninety days after the first infusion, the cancer cells returned in force, filling the bone marrow once again. The patient did not develop antibodies that rejected the therapy, so the team administered a second dose of the engineered cells. This time, the response was less complete, reducing the cancer cells but not eliminating them. Despite the eventual return of the disease, the patient survived for more than eighteen months after the first treatment, a duration that suggests the therapy provided meaningful relief even if it was not a permanent cure. The patient ultimately passed away from a separate infection, but the case demonstrated that targeting SRRM2 could be a viable strategy for patients who have run out of other options.

The researchers conclude that SRRM2 represents a promising new target for treating multiple myeloma, particularly for those with tumors growing outside the bone marrow. The therapy showed high specificity, attacking the cancer while sparing healthy cells, and offered a safer profile than existing treatments. The primary limitation observed was the short lifespan of the engineered cells, which failed to persist long enough to prevent the cancer from returning. This suggests that future improvements might focus on helping these cells survive longer in the body or combining them with other treatments to maintain their effectiveness. While this single case does not prove the therapy works for everyone, it provides a clear example that targeting this specific protein can lead to rapid tumor shrinkage and symptom relief in difficult cases, opening a new path for further investigation.